Details of the Drug

General Information of Drug (ID: DMIXMYK)

• Drug Name: Arfolitixorin
• Synonyms: (6R)-5,10-Methylenetetrahydrofolate; Modufolin; UNII-Z8R4A37V9Q; 31690-11-6; Methylenetetrahydrofolic acid, L-(+)-; (6R)-5,10-methylenetetrahydrofolic acid; CHEBI:1989; Z8R4A37V9Q; L-(+)-methylenetetrahydrofolic acid; 31690-11-6 (free); 5,10-methylene-THF; 5,10-methylenetetrahydrofolate; 3432-99-3; (4-((R)-3-amino-1-oxo-1,2,5,6,6a,7-hexahydroimidazo[1,5-f]pteridin-8(9H)-yl)benzoyl)-L-glutamic acid; N-({4-[(6ar)-3-Amino-1-Oxo-1,2,5,6,6a,7-Hexahydroimidazo[1,5-F]pteridin-8(9h)-Yl]phenyl}carbonyl)-L-Glutamic Acid; N-{4-[(6aR)-3-amino-1-oxo-1,2,5,6,6a,7-hexahydroimidazo[1,5-f]pteridin-8(9H)-yl]benzoyl}-L-glutamic acid; Arfolitixorin [USAN]; 6R-MTHF; Arfolitixorin (USAN/INN); SCHEMBL186747; CHEMBL1234270; DTXSID60185584; ISO-901; BCP09003; ZINC4228243; (6R)-5,10-MTHF; WHO 10689; DB12676; 5,10-methylene-(6r)-tetrahydrofolic acid; 5,10-methylene,5,6,7,8-tetrahydrofolate; D11447; Q26995704; (6r,s)-5,10-methylene-5,6,7,8-tetrahydrofolic acid; [6R]-5,10-methylenetetrahydrofolate ([6R]-5,10- MTHF); UNII-0SXY5ET48B component QYNUQALWYRSVHF-OLZOCXBDSA-N; (S)-2-(4-((R)-3-Amino-1-oxo-5,6,6a,7-tetrahydroimidazo[1,5-f]pteridin-8(1H,4H,9H)-yl)benzamido)pentanedioic acid; N-({4-[(6aR)-3-amino-1-oxo-1,4,5,6,6a,7-hexahydroimidazo[1,5-f]pteridin-8(9H)-yl]phenyl}carbonyl)-L-glutamic acid

Indication

Disease Entry	ICD 11	Status	REF
Colorectal cancer	2B91.Z	Phase 3	[1]

• Drug Type: Small molecular drug
• Chemical Identifiers:
  Formula: C20H23N7O6
  Canonical SMILES: C1C2CN(CN2C3=C(N1)N=C(NC3=O)N)C4=CC=C(C=C4)C(=O)NC(CCC(=O)O)C(=O)O
  InChI: InChI=1S/C20H23N7O6/c21-20-24-16-15(18(31)25-20)27-9-26(8-12(27)7-22-16)11-3-1-10(2-4-11)17(30)23-13(19(32)33)5-6-14(28)29/h1-4,12-13H,5-9H2,(H,23,30)(H,28,29)(H,32,33)(H4,21,22,24,25,31)/t12-,13+/m1/s1
  InChIKey: QYNUQALWYRSVHF-OLZOCXBDSA-N
• Cross-matching ID:
  PubChem CID: 135398645
  ChEBI ID: CHEMBL1989
  CAS Number: 31690-11-6
  UNII: Z8R4A37V9Q
  DrugBank ID: DB12676
  TTD ID: DHY6S0
• Drug ADMET Endpoint Profile (DAE)NEW: Click to Jump to the Detailed DAE Information of This Drug

References

• [1] ClinicalTrials.gov (NCT03750786) A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer (AGENT). U.S. National Institutes of Health.